Literature DB >> 2768794

Indocyanine green intrinsic hepatic clearance as a prognostic index of survival in patients with cirrhosis.

C Merkel1, M Bolognesi, G F Finucci, P Angeli, L Caregaro, M Rondana, A Gatta.   

Abstract

The prognostic value of quantitative liver function tests in patients with cirrhosis is not clearly established. Indocyanine green intrinsic hepatic clearance (ICG-IHC) is a quantitative liver function parameter independent of liver blood flow, which was shown to correlate strictly with the Child-Turcotte-Pugh (CTP) classification of severity of liver disease. Few data are available on its prognostic value. One hundred and five patients with cirrhosis were studied. ICG-IHC was measured according to the 'sinusoidal perfusion' model. Median ICG-IHC in the whole series was 374 ml/min (interquartile range: 214-496 ml/min). During follow-up (mean 31 months; max. 48 months) 38 patients died. The probability of survival was lower in patients with ICG-IHC lower than 300 ml/min (35% at 48 months) than in patients with ICG-IHC between 300 and 1000 ml/min (70%), or with ICG-IHC over 1000 ml/min (80%) (P = 0.02). Also s-albumin (P less than 0.01), ascites (P = 0.001) and CTP class (P less than 0.001) were significant predictors of survival. On incorporation of age, sex, etiology of cirrhosis, ICG-IHC, s-albumin, s-bilirubin, prothrombin index, ascites and encephalopathy, into a multiple regression analysis according to the Cox's model, the results showed only ascites and s-albumin to be independent significant predictors of survival, while ICG-IHC was not among the covariates independently predictive of survival. When CTP class was added to the investigated covariates, the results showed it as the only independent predictor of survival.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2768794     DOI: 10.1016/0168-8278(89)90070-6

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

1.  Are prealbumin plasma levels linked to amino acid supply from peripheral tissues in liver cirrhosis?

Authors:  P Amodio; S Bellon; C Merkel; M Bolognesi; A Gatta
Journal:  Amino Acids       Date:  1992-10       Impact factor: 3.520

2.  Intermittent pringle maneuver and hepatic function: perioperative monitoring by noninvasive ICG-clearance.

Authors:  José Guilherme Tralhão; Emir Hoti; Bárbara Oliveiros; Ana M Abrantes; M Filomena Botelho; F Castro-Sousa
Journal:  World J Surg       Date:  2009-12       Impact factor: 3.352

3.  Parameters of microsomal and cytosolic liver function but not of liver perfusion predict portal vein velocity in noncirrhotic patients with chronic hepatitis C.

Authors:  C Herold; P Berg; D Kupfal; D Becker; D Schuppan; E G Hahn; H T Schneider
Journal:  Dig Dis Sci       Date:  2000-11       Impact factor: 3.199

4.  Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis.

Authors:  C Merkel; M Bolognesi; S Bellon; S Bianco; B Honisch; H Lampe; P Angeli; A Gatta
Journal:  Gut       Date:  1992-06       Impact factor: 23.059

5.  Oral supplementation with branched-chain amino acids improves survival rate of rats with carbon tetrachloride-induced liver cirrhosis.

Authors:  K Kajiwara; M Okuno; T Kobayashi; N Honma; T Maki; M Kato; H Ohnishi; Y Muto; H Moriwaki
Journal:  Dig Dis Sci       Date:  1998-07       Impact factor: 3.199

6.  Can quantitative tests of liver function discriminate between different etiologies of liver cirrhosis?

Authors:  Christoph Herold; Sabine Regn; Marion Ganslmayer; Matthias Ocker; Eckhart G Hahn; Detlef Schuppan
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

7.  Prognostic value of (13)C-phenylalanine breath test on predicting survival in patients with chronic liver failure.

Authors:  I Gallardo-Wong; S Morán; G Rodríguez-Leal; B Castañeda-Romero; R Mera; J Poo; M Uribe; M Dehesa
Journal:  World J Gastroenterol       Date:  2007-09-14       Impact factor: 5.742

8.  Evaluation of quantitative liver function tests in HIV-positive patients under anti-retroviral therapy.

Authors:  M Miller; A Kahraman; B Ross; M Beste; Guido Gerken
Journal:  Eur J Med Res       Date:  2009-09-01       Impact factor: 2.175

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.